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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYWe utilized induced pluripotent stem cells (iPSCs) derived from Huntington’s disease (HD) patients as a human model of HD and
determined that the disease phenotypes only manifest in the differentiated neural stem cell (NSC) stage, not in iPSCs. To understand
the molecular basis for the CAG repeat expansion-dependent disease phenotypes in NSCs, we performed transcriptomic analysis of
HD iPSCs and HD NSCs compared to isogenic controls. Differential gene expression and pathway analysis pointed to transforming
growth factor b (TGF-b) and netrin-1 as the top dysregulated pathways. Using data-driven gene coexpression network analysis, we
identified seven distinct coexpression modules and focused on two that were correlated with changes in gene expression due to the
CAG expansion. Our HD NSC model revealed the dysregulation of genes involved in neuronal development and the formation of
the dorsal striatum. The striatal and neuronal networks disrupted could be modulated to correct HD phenotypes and provide ther-
apeutic targets.INTRODUCTION
Huntington’s disease (HD) is a debilitating, inherited neu-
rological disorder characterized by chorea, psychological
changes, and cognitive decline leading to dementia (Vic-
torson et al., 2014). These symptoms are correlated with
loss of striatal and cortical neurons in the brain (Ehrlich,
2012). HD is caused by a CAG expansion mutation coding
for the polyglutamine tract located in the N-terminal re-
gion of the huntingtin protein (HTT) (The Huntington’s
Disease Collaborative Research Group., 1993). At this
time, there is no cure for HD or treatments to delay its onset
and progression (Videnovic, 2013).
Standard HD models include transgenic animal models,
immortalized rodent and human cell lines, and post-mor-
tem tissue from HD patients (Bard et al., 2014; Lee et al.,
2013). These models have been very useful in understand-
ing some mechanisms behind HD pathogenesis; however,
they do not fully represent human HD pathology (Kaye
and Finkbeiner, 2013). Particularly important is the field’s
reliance on HD mouse models, which do not account for
the potential to miss key drug targets, the effects of poly-
morphisms on human protein toxicity, human-specific
cell subtypes, and transcription factor binding sites spe-
cific to humans. A promising complementary approach
for modeling HD is the use of human induced pluripotent
stem cells (iPSCs) derived from HD patient somatic cells
(An et al., 2012; Zhang et al., 2010). HD iPSCs harboringStem Cell Repmutant HTT protein (mHTT) have the potential to model
the disease more accurately, as they are untransformed
and capable of differentiating into multiple types of neu-
ral tissue. Human iPSCs also provide the advantage of
following the progress of the disease during neural devel-
opment and detecting early pathological changes—the
presymptomatic stage. iPSCs provide a platform for sys-
temic genomic profiling and drug screening and are a
promising tool for cellular replacement therapy in HD
patients.
We have previously established HD-patient-derived
iPSCs and corrected their genetic defect through the
use of homologous recombination-based gene targeting
methods (An et al., 2012). Characterization of these iso-
genic lines and derivative neural precursors showed that
correction of the expanded polyglutamine region to a
non-disease causing length resulted in a normalization of
cellular phenotypes consistent with several well-estab-
lished and reproducible aspects of the disease—cell death,
loss of brain-derived neurotrophic factor (BDNF) expres-
sion, and reduction of mitochondrial respiratory capacity,
among other cellular phenotypes (An et al., 2012; Zhang
et al., 2010). These phenotypes were apparent in differenti-
ated neural stem cells (NSCs) but not the pluripotent stem
cell fate. In a separate study, HD iPSCs displayed elevated
lysosomal activity indicating a disruption in cellular main-
tenance and protein degradation (Camnasio et al., 2012).
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Figure 1. RNA-Seq Analysis of HD Isogenic Stem Cell Model
(A) Schematic illustration of experimental design and analysis. iPSCs reprogrammed from HD patient fibroblasts were genetically corrected
for the HTT mutation using traditional homologous recombination via a targeting construct. Resulting isogenic iPSC pairs and differ-
entiated isogenic NSC pairs were grown in tandem and plated as replicates for RNA isolation and RNA-seq analysis. There are eight
biological replicates (BR) of each-corrected iPSCs, HD iPSCs, corrected NSCs, and HD NSCs: a total of 32 samples.
(B) Multi-dimensional scaling based on VSD-normalized expression levels of the top 5,000 most variable genes.
(C) Number of DE genes across comparisons at <0.01 false discover rate (FDR) threshold. Green bars represent the numbers of down-
regulated genes and red upregulated for each comparison.
(legend continued on next page)
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in striatal medium spiny neurons (MSNs) generated from
HD and control patient iPSCs (HD iPSC Consortium,
2012). HDMSNs display altered electrophysiological prop-
erties including differences in their ability to fire sponta-
neous and evoked action potentials and to regulate intra-
cellular calcium signaling.
Our initial endeavors in characterizing our isogenic
iPSCs lines included a microarray-based large-scale gene
expression analysis comparing the HD iPSCs with the
corrected line C116 iPSCs (An et al., 2012). These studies
were restricted to a comparison of only the iPSCs lines
but yielded several useful insights regarding the biology
of these established cell models. Specifically, we found
that global gene expression remained essentially un-
changed at the iPSC state upon analysis of isogenic pairs
(HD iPSCs versus corrected iPSCs). We identify an order
of magnitude fewer significantly differentially expressed
(DE) genes when compared to a separate experiment,
evaluating a non-isogenic pair of HD iPSCs versus normal
iPSCs derived from an unrelated healthy individual,
likely due to differences in genetic background as found
in other studies (Fogel et al., 2014). The low degree of
DE genes between corrected and uncorrected isogenic
iPSCs supports several important points regarding the
biological characterization of this HD model: (1) isogenic
gene modification does not dramatically alter the ex-
pression profile of these cells, (2) HTT gene correction
does not markedly alter gene expression at the iPSCs
state—consistent with disease biology, (3) gene expres-
sion analysis in controlled isogenic cell line studies may
represent a cleaner approach to discovery of disease-
relevant pathway effects, and (4) further analysis in dis-
ease-affected cell types may allow the ability to resolve
disease-specific coexpression traits unique to those cell
types.
Here, we present transcriptomic and bioinformatic anal-
ysis of disease-relevant and non-relevant cell types in tan-
dem with an isogenic human stem cell model of HD. DE
analysis and weighted coexpression analyses confirmed
the cell-specific nature of gene expression changes due
to mHTT. We used weighted gene coexpression network
analysis (WGCNA) to analyze the non-disease and disease
states of our isogenic HD stem cell model and determine
clusters of co-regulated genes, known as modules, that
define each state (Langfelder and Horvath, 2008). The(D) Heatmap representing DE genes in any of the comparisons of HD
rows) are clustered by similarity. Shades of red represent upregulatio
(E) Heatmap representing relative expression levels of the DE genes w
of <0.01. Gene names are listed on the right. The nomenclature is the
HD-NSC and its corresponding sample number (HD_NSC_#).
(F) Table summary of top upstream regulators in HD versus corrected
See also Tables S1 and S2.
Stem Cell Repmodules were analyzed by Genemania, functionally an-
notated by DAVID, analyzed by Enrichr, and the top,
most connected transcripts (hubs) were studied in detail.
Inclusion of HD iPSCs, which do not show a phenotype,
enabled the isolation of coexpression traits specific to
the HD NSCs and the identification of pathways involved
in HD pathogenesis. Further modulation of key members
of these signaling pathways rescued some HD disease
phenotypes.RESULTS
Analysis of Differential Gene Expression in
Undifferentiated and Differentiated HD Induced
Pluripotent Stem Cell Models
Previously, we characterized the genetically corrected lines
of HD patient-derived iPSCs and found that a phenotype
was apparent in the differentiated NSC stage but absent
at the pluripotent stem cell state (Figure 1A) (An et al.,
2012). We aimed to use this neural-specific correlation be-
tween disease genotype and disease phenotype to inform
our global analysis of transcriptional changes that occur
as a result of mHTT in our established human HD isogenic
stem cell model (Figure 1A). Both iPSCs and NSCs were
grown in tandem for three passages and eight replicates
of each line were plated. Libraries were made from all 32
samples and sequenced using a HiSeq2000 sequencer to
an average depth of 23.7 million 50 bp, paired-end reads
per sample, 87% uniquely mapping to the human refer-
ence genome. Multidimensional scaling (MDS) showed
distinct clustering of sample groups (Figure 1B). All iPSCs
samples fall within a distinct cluster from NSCs samples.
HD and corrected NSCs samples fall within distinct clusters
dependent on the CAG length. By contrast, HD and cor-
rected iPSC samples do not clearly delineate from each
other. This is consistent with the distinct phenotypes
found in HD NSCs and not HD iPSCs.
EdgeR was used to identify DE genes in each of the two
paradigms (NSCs, iPSCs). We assessed the effect of HDmu-
tation in both groups (HD iPSCs versus corrected iPSCs; HD
NSCs versus corrected NSCs, false discovery rate threshold:
1%). We identified 4,466 DE genes when comparing
HDNSCs and corrected NSCs, of which 2,367 were upregu-
lated and 2,099 were downregulated in the disease stateversus control. Samples (in columns noted H1–H16) and genes (in
n, shades of green downregulation.
hen comparing HD NSCs and corrected NSCs at an adjusted p value
NSC corrected line C116 and the sample number (C116_NSC_#) and
NSC samples via IPA analysis.
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Figure 2. WGCNA Analysis of HD Isogenic Stem Cell Model Reveals Drivers of HD Phenotypes in NSCs
(A) Dendogram of genes clustered based on topological overlap. Identified modules are defined by colors.
(B) Dendrogram representing the seven modules identified by WGCNA. The gray module represents genes that are not included in any of the
modules.
(C–I) Heatmap (top) and first principal component (eigengene, bottom) of expression data for genes in WGCNA modules across 32 samples.
Samples are labeled by group, and the number of genes in each module is in parentheses. Of seven distinct modules defined, turquoise and
blue modules are characterized by coexpression traits consistent with expression differences between the iPSC and NSC state (C and D),
(legend continued on next page)
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(Figure 1C; Table S1). In contrast, only 370 genes were DE
when comparing HD iPSCs to corrected iPSCs (Figure 1C;
Table S1). This greater than 10-fold difference in globally
DE genes in the disease/corrected NSC pair compared to
the same cell pairs in the iPSC state correlates with the neu-
ral specific disease phenotypes in HD. Clustering of these
DE genes across all samples shows discrete clusters of genes
with distinct expression patterns between NSC and iPSC
samples (Figure 1D). Functional annotation of the DE
genes between HD NSCs and corrected NSCs groups are
listed, representing the most significant changes in gene
expression at the NSC state due to CAG repeat length (Fig-
ure 1E; Table S2). Functional annotation of the DE genes
when comparingHDNSCs and correctedNSCs highlighted
several gene ontology (GO) categories, including extracel-
lular matrix organization (p = 0.000027), regulation of
synapse assembly (p = 0.000097), mammalian pheno-
type-abnormal survival or perinatal lethality (p = 2.8e-7),
and numerous genes involved in axonal guidance such
as netrin-1, semaphorin 3D (SEMA3D), BDNF, and cad-
herin family members. Targets of the transcription factor
SMAD3 were overrepresented (p = 0.0018), and the top
WikiPathway was BDNF signaling (p = 0.0053).
Ingenuity Pathway Analysis (IPA) of the genes that areDE
between HDNSCs and corrected NSCs highlighted, among
the top upstream regulators, transforming growth factor
b (TGF-b), b-estradiol, and tumor necrosis factor alpha
(TNF-a) (Figure 1F). TGF-b is particularly interesting as it
plays a critical role in temporal neurogenesis where the
onset of TGF-b signaling determines the overall lifespan
of the temporal lineage (Dias et al., 2014). HTT is required
for neurogenesis and mHTT disrupts striatal and cortical
neuronal development (Molina-Calavita et al., 2014; Mo-
lero et al., 2009). The role of TGF-b has not been investi-
gated extensively in HD but has been in other neurological
diseases, such as Alzheimer’s disease and Parkinson’s dis-
ease, where levels of this factor are elevated (Vawter et al.,
1996; Zetterberg et al., 2004). Levels of TGF-b are altered
in cortical neurons and in peripheral blood of HD patients,
as well as in mouse models of HD (Battaglia et al., 2011;
Kandasamy et al., 2011). Microarray and bioinformatics
analysis of a HD neuronal Caenorhabditis elegansmodel re-
vealed Wnt/TGF-b as relevant to pathogenesis (Tourette
et al., 2014). Similarly, a link with b-estradiol has not
been well studied, but it has been shown that male HD
transgenic rats display decreased levels of 17b-estradiol at
older ages (Bode et al., 2008). Lastly, HD is associated
with increased levels of proinflammatory cytokines suchwhereas other individual modules define expression profiles consisten
and F) y axis is first principal component for (C)–(I).
(J) Summary of all modules by sample group.
See also Tables S3, S4, S5, and S6.
Stem Cell Repas TNF-a, suggesting a role in inflammatory response,
which may contribute to HD progression (Bjo¨rkqvist
et al., 2008; Hsiao et al., 2014).
Network Analysis Reveals Modules of Genes
Associated with the Pathogenic CAG Repeat
Wechose to take advantage of themulti-differentiated state
of our experimental design by implementing a coexpres-
sion network analysis that could further inform our under-
standing of the biology of HD. WGCNAwas performed on
the full RNA sequencing (RNA-seq) expression data across
the four distinct cellular states (32 samples) (Figure 1A).
WGCNA identifies modules of coexpressed genes that
reflect shared functions or cellular components. In addi-
tion, identification of highly connected genes (hubs) al-
lows us to pinpoint genes and pathways relevant to further
analysis. WGCNA revealed seven distinct modules repre-
senting highly co-expressed networks of genes (Figures
2A and 2B; Table S3). A module first principal component
(eigengene) can be used to visualize the expression levels
for each module across the 32 samples. This analysis
showed that some modules (blue, turquoise) represented
differences across cell types, whereas for others (red, black),
the eigengene was correlated primarily with genotype (Fig-
ures 2C–2J).
We used DAVID to assess the GO annotation of each
module (Table S4). The two largest modules by size, blue
and turquoise, represent expression changes that clearly
delineate between NSC and iPSC sample groups, strongly
reflecting expression differences between the iPSC and
the differentiated NSC states (Figures 2C, 2D, and 2J).
Top biological processes associated with the blue module
(downregulated in NSCs relative to iPSCs) include transla-
tion, metabolic process, ribosome biogenesis, and pro-
teasomal catabolic process, while conversely, processes
associated with the turquoise module (upregulated in
NSCs relative to iPSCs) include regulation of transcription,
DNA-dependent chromatin modification, chromosome
and chromatin organization, cell cycle, and response to
DNA damage (Table S4).
We further identified two coexpressionmoduleswith fea-
tures highly relevant to the HD phenotype (Figures 2E and
2F).We hypothesize that the genes in thesemodules would
be more closely relevant to HD as we observe a relevant
phenotype in neuronal states and less difference in plurip-
otent stem cell states. The black (59 genes) and red (73
genes)modules represent genes that are highly upregulated
in HD NSCs, while expression differences between HD andt with changes in gene expression in NSCs due to CAG expansion (E
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control are less pronounced in the iPSC state (Figures 2E,
2F, and 2J). Functional annotation highlighted differences
in the biological processes (GO terms) associated with
gene members of the red and black modules. Most signifi-
cant biological processes in the red module include en-
riched terms neuron differentiation, neuron development,
morphogenesis, axonogenesis and axon guidance, whereas
no terms were significantly associated with the black
module after multiple testing correction (Table S5). The re-
maining three modules, brown, yellow, and green, (Figures
2G–2I) showedmodest correlation with either the cell type
or the genotype.
Identifying the Top Genes within the Consensus
Modules Based on Significance and Fold Change
Having identified two modules of interest with regard to
cell-type-specific gene expression changes due to mHTT,
we further focused on the members of these two groups
and the gene expression fold changes at the NSC state
(HD versus corrected). At a p value cutoff of <0.01, all mem-
bers of the black module, and all but one in the redmodule
are below that threshold (Table S6). A volcano plot of red
and black module members allows further visualization
of the highly significant genes in these two groups, while
also identifying large magnitude fold changes from these
groups (Figure 3A). A log2 fold change cutoff of 1 is shown
(Figure 3A; Table S6). Genes that we found upregulated in
HD NSCs compared to controls were NTN1, CDH2,
DPYSL5, CTNND2, YWHAE, C7orf29, LRRC61, LRRC4B,
SEMA3D, PCDHB15, PCDHB18, UQCC, SPOCK3, and
GRIP1.
Identification of Hub Genes in the Modules
Next, we focused on the genes with the highest intra-
modular connectivity (hub genes), as these are the best
representative of the expression of the entire module
(Langfelder et al., 2013) and may represent points of bio-
logical interest in defining the HD phenotypes. Network
plots for the red and black modules, highlighting the top
most connected genes, are represented in Figures 3B and
3C (Figures S1A–S1E show the other modules).
For the red module, four hub genes were identified:
SEMA3D,CDH2, IRS1, andAPBB2 (Figure 3B). Semaphorins
are a class of secreted and membrane proteins that act as
growth cone guidance molecules through the receptors
plexins and are coupled to RRAS. Previously, we identified
RRAS as a therapeutic target for HD using a siRNA screen
to the druggable genome (Miller et al., 2012). Semaphorin
4D inhibition was shown to ameliorate neuropathology
and some cognitive deficits in HD mouse models (South-
well et al., 2015). Cadherin has been linked directly to
the function of the HTT protein (Lo Sardo et al., 2012).
The HTT protein evolved to acquire a unique regulatory ac-1028 Stem Cell Reports j Vol. 5 j 1023–1038 j December 8, 2015 j ª2015 Thtivity for controlling neural adhesion via ADAM10-N-cad-
herin. Mouse striatal neurons expressing mHTT have
altered N-cadherin levels and neuritogenesis (Reis et al.,
2011). Insulin growth receptor substrate 1 (IRS1) has not
been investigated in HD, but mice lacking this protein are
long-lived and lack many of the diseases of aging (Selman
et al., 2008). Finally, the amyloid-b precursor protein-bind-
ing, family B,member 2 (APPB2) is involved inAPP process-
ing and levels of phosphorylation (Sakuma et al., 2009).
For the black module, eight hub genes were identified:
HSPB8, DOK5, SH3BGRL2, VGLL3, LYN, GRIP1, FAM131B,
and EFEMP1 (Figure 3C). A few of these hub genes particu-
larly stand out with respect to HD. AMPA receptors
generate intracellular signals from the cell surface to the
nucleus through the Lyn-MAPK pathway, which may
contribute to synaptic plasticity by regulating the expres-
sion of BDNF (Hayashi et al., 1999). SH3BGL2 (intersectin
2) is involved in clathrin-mediated endocytosis and is
a partner of dynamin (Evergren et al., 2007). DOK5 is a
substrate for TrkB and TrkC receptors (Shi et al., 2006).
Genemania network analysis of black and red modules
are shown in Figures 3D and 3E highlighting the genes
interconnections.
Enrichment Analysis of the Modules
As an alternative approach to rank and visualize enriched
terms, we used the web-based gene list enrichment analysis
tool Enrichr. Enrichr tools were applied to all seven
modules (Table S6). We found that the genes of the black
module are statistically enriched for genes associated with
the mouse gene atlas term dorsal striatum (Figure 4A).
We used GeneMANIA, a gene function tool that allows
visualization between these genes with respect to coexpres-
sion, co-localization, and protein interaction to generate
an annotated Cytoscape network for the black module
(Figure 4B). We found DARPP-32 to be associated with a
number of these enriched networks. PPP1R1B (DARPP-32)
is downregulated in NSCs but not iPSCs in our RNA-seq
data, and differential expression of DARPP-32 has been
confirmed by qPCR analysis (Figure 4C) in distinct NSC cul-
tures. DARPP-32 is an abundant protein expressed in stria-
tal MSNs and its expression levels decrease in HD mouse
models and human postmortem tissue.
Given the blackmodule’s enrichment to themouse stria-
tum,we next evaluated if thismodule is associatedwith the
human striatum during development. We evaluated if any
of the HD-relevant modules were enriched for striatum-
specific marker genes identified from a genome-wide adult
brain mouse atlas (Lein et al., 2007). While the top 100
genes with the most striatum-specific expression were
selected, only 49 of these were actually expressed in our da-
taset. From the 50 mouse homologous genes in the black
module, only Dach1 is among the most striatum-specifice Authors
Figure 3. Volcano and Hub Connectivity of Module Genes, Visualized for the Red and Black Modules
(A) Volcano plot of genes in the red and black WGCNA modules, at p < 0.1. Individual top fold change genes are labeled.
(B and C) Network plot depicting the top connections for each module. Most highly connected module members (hub genes) are shown for
each group.
(D and E) Genemania network analysis diagram of red and black modules. All module members in black, with genes of interest highlighted
in red.
See also Figure S1.marker genes, while there was no overlap with the 61
mouse homologous genes in redmodule.We also evaluated
if the black or red modules were enriched for genes associ-
ated with human striatum during development, identified
from gene expression data in prenatal human striatum
(from 2 to 20 weeks of age) (Onorati et al., 2014). We found
that the red module was statistically enriched for DE genes
found to be upregulated in the developing human striatum
(ELOVL4, KIF5C, MTSS1, NEFM, NRXN1, NTN1, PCP4,
STK32B, and TMEM88; Z score = 4.18). Using WGCNA
analysis, the group also identified a module, named M25,
whosemembers are highly expressed in the developing hu-Stem Cell Repman striatum (Onorati et al., 2014). We found that the
black and red modules were statistically enriched for
genes found in the M25 module (Figure 4D). The genes
matching the highly expressed genes in the striatum were
BEX2, C7orf13, FAM131B, GREB1L, GRM2, LPPR1, LYN,
MAP2, MMP11, MVD, NUAK1, POU3F1, PPARGC1A,
SH3BGRL2, SRCIN1, TNFRSF21, and UQCC. In addition
to the black module, we also evaluated other key striatal-
specific genes identified in the Onorati study using our
RNA-seq expression dataset (Table S1). Well known genes
in human striatal development CTIP2, DARPP-32, ISL1,
TBR1, FOXP1, and PAX6 are all downregulated in HDorts j Vol. 5 j 1023–1038 j December 8, 2015 j ª2015 The Authors 1029
Figure 4. The Black Module Is Linked to Expression of Genes in the Striatum
(A) Gene enrichment of black module gene members shows significant enrichment of genes associated with dorsal striatum based on the
Mouse Gene Atlas list using the Enrichr tool.
(B) Subsequent visualization of networks associated with these five genes using the Genemania tool.
(C) qPCR analysis of DARPP-32 mRNA levels in HD and C116 NSC samples (n = 5 BR). Five independent BR are displayed as
mean ± SD.
(legend continued on next page)
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NSCs compared to control NSCs (Figure S2). Interestingly,
FOXP2 is upregulated in HD NSCs compared to control
NSCs, and its expression becomes more restricted in the
human striatumduring development (Onorati et al., 2014).
Because degeneration of MSNs is the pathological hall-
mark of HD, we used three independently generated lists
of MSN-enriched gene sets, by laser-captured HD patient
MSNs (Hodges et al., 2006), tagged ribosome profiling in
adult mice (Heiman et al., 2008) and by FACS-sorting of
D1/D2 MSNs (Lobo et al., 2006) for analysis. We found
that in the red module, 16 of the 61 mouse homolog genes
were MSN-specific marker genes, though the enrichment
was not significant (Z score = 2.03). Moreover, the redmod-
ule also included NRXN1, one of the nine genes differen-
tially enriched in striatonigral (D1) neurons (Lobo et al.,
2006).
We note that our coexpressionmodules identified highly
upregulated genes at the HDNSC state in the black and red
modules compared to control NSCs. Coexpression mod-
ules representing highly downregulated genes at the HD
NSC state were not identified by the WGCNA analysis
(Figure 2J). In particular, reduced expression of BDNF is a
well-characterized phenotype in HD models and in brains
of HD patients. BDNF is downregulated in HD NSCs in
our RNA-seq analysis, and as noted above, BDNF signaling
is the top Wikipathway identified among the 100 top
DE genes (p = 0.0053). Using a hierarchical clustering
approach, we identified genes whose expression pattern
follows that of BDNF (Figure S3A). This cluster contains
genes that, while unchanged in iPSCs, are downregulated
in HD-NSCs compared to control NSCs and may therefore
represent genes that are dysregulated in the NSC lineage of
HD patients. It included several genes known to be associ-
ated with HD and striatal development, such as BDNF,
TGM2, and DARPP-32, as well as five cadherins (CDH15,
CHD6, PCDHGA3, PCDHGB7, and PCDHGC4) (Figure S3B).
Genemania shows the coexpression network for this clus-
ter of genes (Figure S3C). Enrichr links this module to dor-
sal striatum as well, and genes are enriched for the M25
module (Onorati et al., 2014). Further, this group contains
a key constituent of the TNF upstream regulatory pathway
that was identified in our IPA analysis of DE genes (Fig-
ure 1F): TNFRSF1B (TNFR-II or p75), whose expression
highly correlates with BDNF. Based on these findings, we
evaluated if the black or red modules were enriched for
genes-associated BDNF depletion, identified from gene
expression striatal profiles from BDNF knockout mice
(Strand et al., 2007).We found that the redmodule was sta-(D) Both the red and black modules have genes enriched for human str
CTNND2, FAM20C, GNAZ, GPRIN3, HBEGF, KIF5C, MTSS1, MURC, NEFM, NR
TMEM88, TPM1, TUBB3, and ZN597.
See also Figures S2 and S3.
Stem Cell Reptistically enriched for genes upregulated (five genes:CSRP1,
NTN1, PCYT2, PTPRK, and SEMA3A; Z score = 4.2) and
downregulated (five genes: ACTN1, GNAZ, HBEGF, PCP4,
and TPM1; Z score = 5.03) in the BDNF-KO mice.
We next tested whether genes in HD-associated modules
were enriched for transcription factor binding sites using
the ENCODE chromatin immunoprecipitation sequencing
(ChIP-seq) significance tool (Auerbach et al., 2013). We
found that both HD modules were enriched for the Ezh2
(Enhancer of zeste homolog 2) factor, with 21 (out of the
58 valid) black module genes (Q value = 3.204e-2) and 28
(out of 65 valid) redmodule genes (Q value = 5.905e-5) hav-
ing a binding site for this particular transcription factor.
EZH2, is the functional enzymatic component of the poly-
comb repressive complex 2 (PRC2), which is involved in
various biological processes, including differentiation,
maintenance of cell identity and proliferation, and stem-
cell plasticity (Margueron and Reinberg, 2011). HTT facili-
tates PRC2 function and this is at least partially mediated
by the physical interaction of full-length wild-type HTT
protein with the Ezh2 and Suz12 PRC2 core component
(Seong et al., 2010).
Therapeutic Targets Can Be Identified from
Bioinformatic Analysis of Expression Data from
HD NSCs
Bioinformatics analysis revealed key signalingmolecules in
neurogenesis, striatal development and axonal guidance.
Consistent with this, two pathways identified relevant
to HD phenotypes include TGF-b (top altered RNA-seq
pathway) and netrin-1 (black module). Both of these path-
ways are required for neurogenesis and are linked to devel-
opment of the striatum. Therefore, we evaluated whether
these pathways were altered in our HD NSC model and if
modulation was neuroprotective.
TGF-b is the top signaling pathway that is altered be-
tween HD and corrected NSCs based on our RNA-seq re-
sults. Therefore, we evaluated TGF-b signaling in our
human HD stem cell model and in zQ175 knockin HD
mice. First, we determined basal levels of TGF-b expression
inHD and correctedNSCs. TGF-b is part of a larger complex
and appears in multiple forms including its precursor form
(60 kDa), its active dimer form (24 kDa), and its inactive
monomer form (12 kDa) (Annes et al., 2003). Using a pan-
TGF-b antibody that recognizes all three TGF-b isoforms,
western blot analysis of HD and corrected NSC lysates
revealed that HD NSCs significantly express more TGF-b
in its precursor, dimer, and monomer forms (Figures 5Aiatum. The matches for the red module are ACTB, C17orf58, CORO2B,
XN1, NTN1, PCDHB12, PCDHB18, PCP4, RAB1F, RND3, SDK1, STK32B,
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Figure 5. TGF-b Expression and SMAD Signaling Is Altered in HD NSCs
(A) TGF-b protein levels in HD (n = 5 BR) and corrected C116 NSCs (n = 5 BR) were determined by western blot and normalization to
a-tubulin.
(B) HD NSCs had elevated TGF-b protein in multiple forms including the TGF-b precursor complex, TGF-b dimer and monomer, compared to
C116 NSCs.
(C) SMAD activation, indicated by phosphorylation of SMAD2 (pSMAD2), was determined in HD and C116 NSCs via western blot by
normalization to SMAD2.
(D) Both corrected and HD NSCs activated the SMAD signaling pathway upon treatment with recombinant human TGF-b1 (10 ng/ml) for
1 hr. Under normal basal conditions, HD NSCs have higher levels of activated pSMAD2 compared to corrected NSCs. Similarly, HD NSCs
treated with TGF-b1 had higher levels of pSMAD2 compared to C116 NSCs. All experiments had five biological replicates per genotype, and
each experiment was repeated three times.
(E) TGF-b protein levels in HD lines (n = 2 BR) and control NSCs (n = 2 BR) were determined by western blot and normalization to a-tubulin.
(F) Densitometry of the western blot shown in (E).and 5B). TGF-b ligands signal through TGF-b receptors
and activate SMAD proteins through phosphorylation of
SMAD2/3 (Dennler et al., 2002). Because TGF-b1 expres-1032 Stem Cell Reports j Vol. 5 j 1023–1038 j December 8, 2015 j ª2015 Thsion is increased in the brain in response to injury (Krupin-
ski et al., 1996), we determined whether recombinant TGF-
b1 could modulate TGF-b signaling in HD NSCs ande Authors
ameliorate HD phenotypes. To test for activation of SMAD
signaling, HD and corrected NSCs were treated with or
without TGF-b1. Both corrected and HD NSCs showed an
increase in pSMAD2 levels upon TGF-b1 treatment
compared to untreated NSCs (Figures 5C and 5D). In basal
conditions without TGF-b1 treatment, HD NSCs expressed
more pSMAD2 than corrected NSCs. Furthermore, TGF-b1
treatment resulted in higher pSMAD2 phosphorylation
expression in HD NSCs compared to corrected NSCs.
Thus, both HD and corrected NSCs can activate SMAD
signaling upon exposure to TGF-b1, however HD NSCs
have more pSMAD2 overall. This could be due to HD
NSCs havingmore TGF-b or to a compensatorymechanism
to combat the HD mutation. To confirm that expression
of TGF-b changes are observed in multiple patient HD
iPSC lines (nonisogenic), we also analyzed HD iPSC
lines ND41656 (CAG57) and ND42222 (CAG109) and
compared them to a control (Figures 5E and 5F). We found
that the levels of TGF-b were higher in NSCs derived from
the HD lines compared to the control.
Elevated levels of TGF-b protein and changes in TGF-b
signaling in HD suggest a potential neuroprotective role
for TGF-b in the brain. Therefore, we determined whether
TGF-b1 could rescue HD-related phenotypes that we iden-
tified in our earlier studies (An et al., 2012; Zhang et al.,
2010). We previously found that HD NSCs had elevated
caspase-3/7 activity compared to corrected NSCs upon
removing serum from cell culture medium. To determine
if TGF-b is protective in a toxicity assay, we cultured cor-
rected or HD NSCs in either (1) their regular NSC media
supplemented with growth factors (complete), or (2) in
basic medium without growth factor but supplemented
either with recombinant TGF-b1 or TGF-b2 for 48 hr.
Both TGF-b1 and TGF-b2 significantly reduced caspase-
3/7 activity in basic conditions (Figure 6A). The reduction
in caspase activity occurred in a dose-responsive manner
(Figure 6B), as higher concentrations of TGF-b1 were
more effective at reducing caspase activity in HD NSCs in
basic conditions. We did not see a significant reduction in
caspase activity in corrected NSCs in basic conditions
with addition of either TGF-b1 or TGF-b2. We also evalu-
ated whether the deficit in maximal respiratory capacity
in HD NSCs was normalized by TGF-b1 treatment. HD
NSCs have deficits in mitochondrial function when
compared to correctedNSCs asmeasured by Seahorse respi-
ration (An et al., 2012). TGF-b1 treatment rescued the respi-
ratory deficit in HD NSCs (Figure 6C).
After confirming that TGF-b protein levels and SMAD
signaling are altered in HD NSCs, we next asked whether
TGF-b levels are also altered in vivo.We analyzed the cortex
and striatum of zQ175 HD knockin mice for TGF-b expres-
sion at 6 and 12months of age. In the cortex, zQ175 homo-
zygous mice had elevated levels of multiple TGF-b proteinStem Cell Repforms compared to wild-type littermate controls. Specif-
ically, zQ175 cortex at 6 months had significantly higher
levels of the TGF-b precursor and dimer and exhibited a
trend in having more TGF-b monomer compared to con-
trols. At 12 months, zQ175 cortex had higher levels of
TGF-b dimer and showed a trend toward having more
TGF-b monomer when compared to controls (Figure 6D).
Results were not as conclusive for the striatum (Figure 6E).
We only observed a significant increase in TGF-bmonomer
in zQ175mice when compared to controls at 12months of
age (Figure 6D). Our zQ175 results support our in vitro find-
ings and suggest that TGF-b expression is elevated in HD
brains.
Next, we investigated if modulation of the genes in the
red module would have a neuroprotective effect in our
HD NSC model. We focused on the axonal guidance mole-
cule netrin-1 (Figures 3A and 3D) since it was one of the
most significantly altered genes in this module that has
defined function in the axonal guidance pathway. Further-
more, netrin-1 is expressed in the striatal ventricular zone
during development, guides the large influx of striatal ma-
trix neurons into the striatum, and is critical to the forma-
tion of fundamental striatal structures (Hamasaki et al.,
2001). As shown in Figures 7A and 7B, the receptors for ne-
trin-1, such as DCC and UNC5D, have increased expres-
sion in HD NSCs as determined by qPCR (Figure 7B).
Elevated levels of netrin-1 and changes in this signaling
pathway in HD may suggest a potential neuroprotective
role for netrin-1 in the brain. To test this, we treated HD
NSCs with recombinant netrin-1. We found that netrin-1
treatment reduced caspase-3/7 activity in growth factor
starved HD NSCs and is potentially neuroprotective (Fig-
ure 7C). We also evaluated whether the deficit in maximal
respiratory capacity in HDNSCs was normalized by netrin-
1 treatment. Netrin-1 treatment rescued the respiratory
deficit in HD NSCs (Figure 7D). The netrin protein levels
were not significantly altered in the zQ175 mice at
12month of age compared to controls asmeasured bywest-
ern blot analysis (data not shown). Perhaps the alteration
occurs early in development and is normalized in adults.DISCUSSION
In our previous work, we found cellular andmolecular phe-
notypes associated with HD in NSCs derived from HD pa-
tient-specific iPSCs when compared to isogenic controls.
The phenotypes we reported included susceptibility to
cellular death as measured by caspase activity and TUNEL
staining, mitochondrial deficits, lower levels of BDNF,
altered cadherin and TGF signaling (An et al., 2012). The
cellular and molecular phenotypes were only associated
with the differentiatedHDNSC state andwere not detectedorts j Vol. 5 j 1023–1038 j December 8, 2015 j ª2015 The Authors 1033
Figure 6. TGF-b Expression Has Neuro-
protective Effects In Vitro and Is Elevated
In Vivo
(A) HD NSCs have elevated caspase-3/7 ac-
tivity upon growth factor withdrawal. This
phenotype is partially rescued by treatment
with either recombinant human TGF-b1 or
TGF-b2 (10 ng/ml) (n = 5 BR per genotype,
each experiment repeated three times).
(B) TGF-b1 ameliorates elevated caspase-
3/7 activity in HD NSCs in a dose response
manner (n = 5 BR per genotype).
(C) Maximal respiratory capacity of HD
NSCs and C116 NSCs was measured in the
presence and absence of TGF-b (N = 6 BR per
genotype, each experiment repeated three
times).
(D) TGF-b expression in the cortex of zQ175
mice at 6 months was higher in the precur-
sor and dimer forms and higher in the dimer
form at 12 months of age (n = 3 BR per
genotype, each experiment repeated three
times).
(E) In the striatum, TGF-b monomer was
elevated in zQ175 compared to wild-type at
12 months, but no significance was seen at
6 months (n = 3 BR per genotype, each
experiment repeated four times).inHD iPSCs. This finding suggests that the first disease phe-
notypes in HD manifest during early development at the
NSC stage. This is interesting because we may be detecting
HD developmental changes that occur early in disease pro-
gression, in our human HD NSC models.
To examine themolecular basis of the phenotypes found
in HD NSCs, we used RNA-seq to measure expression
changes in these cellular states. Inclusion of HD iPSCs,
which do not show a distinct disease-associated pheno-
type, enabled specific isolation of coexpression traits spe-
cific to the HD NSCs and the identification of pathways
involved in HD pathogenesis. WGCNA analysis revealed
the effects of HTT CAG expansion on NSCs and identified
two modules driving HD phenotypes—the black and red
modules. By studying gene expression changes in prenatal1034 Stem Cell Reports j Vol. 5 j 1023–1038 j December 8, 2015 j ª2015 Thhuman striatum during development, usingWGCNA anal-
ysis, another group identified a module they named M25
whose members are highly expressed in the developing
human striatum (Onorati et al., 2014). We found that the
black and red modules were enriched for genes found in
the M25 module, which is associated with human striatal
tissue. In addition to the black and red module, we
also evaluated other key striatal-specific and well known
genes in human striatal development including CTIP2
(BCL11B), DARPP-32 (PPP1R1B), ISL1, TBR1, FOXP1, and
PAX6, which were all downregulated in HD NSCs com-
pared to control NSCs. This is consistent with a number
of studies showing mHTT alters cortical and striatal neuro-
genesis in mouse models of HD (Molero et al., 2009), and
the normal function of HTT is implicated in neurogenesis.e Authors
A B
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Figure 7. Netrin-1 Is Neuroprotective in
HD Stem Cell Model
(A) The expression of netrin-1 mRNA in
increased in HD NSCs (n = 8 BR per genotype,
repeated three times).
(B) The receptors for netrin signaling have
altered expression in HD NSCs (n = 8 BR per
genotype).
(C) HD NSCs have elevated caspase-3/7 ac-
tivity upon growth factor withdrawal. This
phenotype is rescued by treatment with ne-
trin-1 (100 ng/ml) (n = 5 BR per condition,
repeated three times).
(D) Maximal respiratory capacity of HD NSCs
and C116 NSCs was measured in the presence
and absence of netrin-1 (n = 6 BR per ge-
notype, repeated three times).Indeed, knockin HD mice with Q111 repeats exhibited de-
layed striatal cytoarchitecture with altered expression of
markers of MSNs (Molero et al., 2009). The role of develop-
ment in neurodegeneration has been addressed in a related
polyglutamine expansion disease, SCA1 (Serra et al., 2006).
When ATXN1[82Q] expression in SCA1 mice was delayed
during postnatal development, the disease was less severe.
This correlation of genes found in our NSC analysis and in
previous mouse studies in the field support the concept
that NSCs can be a valuable tool for modeling a disease in
a dish.
A question arising from this work is whether develop-
ment sets the stage for the early pathophysiological abnor-
malities in HD and whether we can identify candidate
pathways or genes that will restore neuronal homeostasis
and protect striatal MSNs halting disease progression. We
believe the black and red modules defined in our studies
represent critical cellular pathways that are disrupted in
early HD pathogenesis and that normalization will restore
neuronal homeostasis and prevent neuronal degeneration.
Our bioinformatics analysis revealed key signaling mole-
cules in neurogenesis, striatal development, and axonal
guidance for these modules. To test whether these path-
ways were altered in HD and represented therapeutic
targets for HD, we focused on two signaling pathways:
TGF-b and netrin. During development the striatum forms
from the ventral telencephalon and is dependent upon
BMP/TGF-b inhibition (Kuang et al., 2006) as well as
netrin-1 signaling (Hamasaki et al., 2001). Our studies ofStem Cell RepTGF-b signaling in HD reveal that this signaling pathway
is altered in HD. Both HD NSCs and HD knockin mouse
brains express more TGF-b than wild-type controls.
Furthermore, TGF-b1 is neuroprotective in our NSCmodels
and can ameliorate some HD phenotypes including re-
ducing caspase activity and improving respiratory capacity
in HDNSCs. These results suggest a possible compensatory
mechanism in which HD NSCs express higher levels of
TGF-b in order to compensate for the negative effects
caused by the HD mutation. Our findings show that ne-
trin-1 levels and receptors were altered in HD NSCs. The
addition of axonal guidance molecule was neuroprotective
consistent with the neuroprotective role of netrin-1 after
stroke (Liao et al., 2013). In addition to these two signaling
pathways, our analysis also revealed that the topWikiPath-
way was BDNF signaling for the top 100 genes. This agrees
with the strong correlation of expression changes of BDNF
knockout mice with human HD brain (Kuhn et al., 2007,
Strand et al., 2007) and numerous studies showing that
BDNF is neuroprotective in HD (Crane et al., 2014). All of
these findings support the use of NSCs for studying HD
in its developmental phases.
In conclusion, we report here that a HD NSC model pro-
vides evidence for early disruption of signaling pathways
that are critical to establishing striatal lineage, and re-
storing these pathways either early or late in the disease
process may provide disease-modifying therapies. Future
work will focus on modulating these critical pathways
in vivo to provide therapeutics treatments for HD.orts j Vol. 5 j 1023–1038 j December 8, 2015 j ª2015 The Authors 1035
EXPERIMENTAL PROCEDURES
Culture of iPSCs
All lines of iPSCs were grown on Matrigel (BD Biosciences)
in mTeSR1 defined medium (STEMCELL). Optimal passaging
occurred at 70%–80% confluency andwas performed by treatment
for 1 hr with 1 mg/ml collagenase. For RNA-seq sample prepara-
tion, comparison lines (HD iPSCs, C116 iPSCs) were grown and
expanded in tandem for three passages before collection of total
RNA. The isogenic lines (HD iPSCs and C116 iPSCs) were described
in An et al. (2012) and Zhang et al. (2010) as well as further control
lines. The non-isogenic HD iPSCs lines ND41656 (CAG57) and
ND42222 (CAG109) were obtained from Coriell repository. The
methods for differentiation to NSCs, RNA isolation, RNA-seq,
qPCR, enrichment and network analysis, western blot of NSCs
and zQ175 mice, caspase activity, and seahorse measurements
are found in the Supplemental Experimental Procedures and previ-
ous publications (An et al., 2012; Zhang et al., 2010).
ACCESSION NUMBERS
The accession number for the RNA-seq data reported in this paper
is GEO: GSE74201.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, three figures, and six tables and can be found with this
article online at http://dx.doi.org/10.1016/j.stemcr.2015.11.005.
AUTHOR CONTRIBUTIONS
K.R., M.C.A., and N.Z. carried out experiments. K.R., M.C.A., N.Z.,
S.M., and L.M.E. designed experiments. K.R., M.C.A., N.Z, R.N.O.,
F.G., E.M.R., R.A., B.B., S.M., S.D.M., G.C., and L.M.E. performed
analysis of the data sets. M.C.A., K.R., and L.M.E. wrote the paper.
All authors edited and contributed to the manuscript preparation.
ACKNOWLEDGMENTS
The funding for this research was provided by the CHDI, Inc.
(L.M.E.), NIH T32 AG000266 (L.M.E., R.N.O., and K.R.), and F32
NS080551 (R.N.O.) training grants. We acknowledge the support
of the NINDS Informatics Center for Neurogenetics and Neuroge-
nomics (P30 NS062691).
Received: May 4, 2015
Revised: November 2, 2015
Accepted: November 12, 2015
Published: December 8, 2015REFERENCES
An, M.C., Zhang, N., Scott, G., Montoro, D., Wittkop, T., Mooney,
S., Melov, S., and Ellerby, L.M. (2012). Genetic correction of Hun-
tington’s disease phenotypes in induced pluripotent stem cells.
Cell Stem Cell 11, 253–263.
Annes, J.P., Munger, J.S., and Rifkin, D.B. (2003). Making sense of
latent TGFbeta activation. J. Cell Sci. 116, 217–224.1036 Stem Cell Reports j Vol. 5 j 1023–1038 j December 8, 2015 j ª2015 ThAuerbach, R.K., Chen, B., and Butte, A.J. (2013). Relating genes to
function: identifying enriched transcription factors using the
ENCODE ChIP-Seq significance tool. Bioinformatics 29, 1922–
1924.
Bard, J., Wall, M.D., Lazari, O., Arjomand, J., and Munoz-Sanjuan,
I. (2014). Advances in huntington disease drug discovery: novel
approaches to model disease phenotypes. J. Biomol. Screen. 19,
191–204.
Battaglia, G., Cannella,M., Riozzi, B., Orobello, S.,Maat-Schieman,
M.L., Aronica, E., Busceti, C.L., Ciarmiello, A., Alberti, S., Amico, E.,
et al. (2011). Early defect of transforming growth factor b1 forma-
tion in Huntington’s disease. J. Cell. Mol. Med. 15, 555–571.
Bjo¨rkqvist, M., Wild, E.J., Thiele, J., Silvestroni, A., Andre, R., La-
hiri, N., Raibon, E., Lee, R.V., Benn, C.L., Soulet, D., et al. (2008).
A novel pathogenic pathway of immune activation detectable
before clinical onset in Huntington’s disease. J. Exp. Med. 205,
1869–1877.
Bode, F.J., Stephan, M., Suhling, H., Pabst, R., Straub, R.H., Raber,
K.A., Bonin, M., Nguyen, H.P., Riess, O., Bauer, A., et al. (2008).
Sex differences in a transgenic rat model of Huntington’s disease:
decreased 17b-estradiol levels correlate with reduced numbers of
DARPP32+ neurons in males. Hum. Mol. Genet. 17, 2595–2609.
Camnasio, S., Delli Carri, A., Lombardo, A., Grad, I., Mariotti, C.,
Castucci, A., Rozell, B., Lo Riso, P., Castiglioni, V., Zuccato, C.,
et al. (2012). The first reported generation of several induced
pluripotent stem cell lines from homozygous and heterozygous
Huntington’s disease patients demonstrates mutation related
enhanced lysosomal activity. Neurobiol. Dis. 46, 41–51.
Crane, A.T., Rossignol, J., and Dunbar, G.L. (2014). Use of geneti-
cally altered stem cells for the treatment of Huntington’s disease.
Brain Sci. 4, 202–219.
Dennler, S., Goumans, M.J., and ten Dijke, P. (2002). Transform-
ing growth factor beta signal transduction. J. Leukoc. Biol. 71,
731–740.
Dias, J.M., Alekseenko, Z., Applequist, J.M., and Ericson, J. (2014).
Tgfb signaling regulates temporal neurogenesis and potency of
neural stem cells in the CNS. Neuron 84, 927–939.
Ehrlich,M.E. (2012). Huntington’s disease and the striatalmedium
spiny neuron: cell-autonomous and non-cell-autonomous mecha-
nisms of disease. Neurotherapeutics 9, 270–284.
Evergren, E., Gad, H.,Walther, K., Sundborger, A., Tomilin, N., and
Shupliakov, O. (2007). Intersectin is a negative regulator of dyna-
min recruitment to the synaptic endocytic zone in the central syn-
apse. J. Neurosci. 27, 379–390.
Fogel, B.L., Cho, E., Wahnich, A., Gao, F., Becherel, O.J., Wang, X.,
Fike, F., Chen, L., Criscuolo, C., De Michele, G., et al. (2014). Mu-
tation of senataxin alters disease-specific transcriptional networks
in patients with ataxia with oculomotor apraxia type 2. Hum.Mol.
Genet. 23, 4758–4769.
Hamasaki, T., Goto, S., Nishikawa, S., andUshio, Y. (2001). A role of
netrin-1 in the formation of the subcortical structure striatum:
repulsive action on the migration of late-born striatal neurons.
J. Neurosci. 21, 4272–4280.e Authors
Hayashi, T., Umemori, H., Mishina, M., and Yamamoto, T. (1999).
The AMPA receptor interacts with and signals through the protein
tyrosine kinase Lyn. Nature 397, 72–76.
HD iPSC Consortium (2012). Induced pluripotent stem cells from
patients with Huntington’s disease show CAG-repeat-expansion-
associated phenotypes. Cell Stem Cell 11, 264–278.
Heiman,M., Schaefer, A., Gong, S., Peterson, J.D., Day,M., Ramsey,
K.E., Sua´rez-Farin˜as, M., Schwarz, C., Stephan, D.A., Surmeier, D.J.,
et al. (2008). A translational profiling approach for the molecular
characterization of CNS cell types. Cell 135, 738–748.
Hodges, A., Strand, A.D., Aragaki, A.K., Kuhn, A., Sengstag, T.,
Hughes, G., Elliston, L.A., Hartog, C., Goldstein, D.R., Thu, D.,
et al. (2006). Regional and cellular gene expression changes in hu-
man Huntington’s disease brain. Hum. Mol. Genet. 15, 965–977.
Hsiao, H.Y., Chiu, F.L., Chen, C.M., Wu, Y.R., Chen, H.M., Chen,
Y.C., Kuo, H.C., and Chern, Y. (2014). Inhibition of soluble tumor
necrosis factor is therapeutic in Huntington’s disease. Hum. Mol.
Genet. 23, 4328–4344.
Kandasamy, M., Reilmann, R., Winkler, J., Bogdahn, U., and
Aigner, L. (2011). Transforming growth factor-beta signaling in
the neural stem cell niche: a therapeutic target for Huntington’s
disease. Neurol. Res. Int. 2011, 124256.
Kaye, J.A., and Finkbeiner, S. (2013). Modeling Huntington’s dis-
ease with induced pluripotent stem cells. Mol. Cell. Neurosci. 56,
50–64.
Krupinski, J., Kumar, P., Kumar, S., and Kaluza, J. (1996). Increased
expression of TGF-beta 1 in brain tissue after ischemic stroke in hu-
mans. Stroke 27, 852–857.
Kuang, C., Xiao, Y., Yang, L., Chen, Q.,Wang, Z., Conway, S.J., and
Chen, Y. (2006). Intragenic deletion of Tgif causes defectsin brain
development. Hum. Mol. Genet. 15, 3508–3519.
Kuhn, A., Goldstein, D.R., Hodges, A., Strand, A.D., Sengstag, T.,
Kooperberg, C., Becanovic, K., Pouladi, M.A., Sathasivam, K.,
Cha, J.H., et al. (2007). Mutant huntingtin’s effects on striatal
gene expression in mice recapitulate changes observed in human
Huntington’s disease brain and do not differ withmutant hunting-
tin length or wild-type huntingtin dosage. Hum. Mol. Genet. 16,
1845–1861.
Langfelder, P., and Horvath, S. (2008). WGCNA: an R package
for weighted correlation network analysis. BMC Bioinformatics
9, 559.
Langfelder, P., Mischel, P.S., and Horvath, S. (2013). When is hub
gene selection better than standard meta-analysis? PLoS ONE 8,
e61505.
Lee, C.Y., Cantle, J.P., and Yang, X.W. (2013). Genetic manipula-
tions of mutant huntingtin in mice: new insights into Hunting-
ton’s disease pathogenesis. FEBS J. 280, 4382–4394.
Lein, E.S., Hawrylycz, M.J., Ao, N., Ayres, M., Bensinger, A., Ber-
nard, A., Boe, A.F., Boguski, M.S., Brockway, K.S., Byrnes, E.J.,
et al. (2007). Genome-wide atlas of gene expression in the adult
mouse brain. Nature 445, 168–176.
Liao, S.J., Gong, Q., Chen, X.R., Ye, L.X., Ding, Q., Zeng, J.S., and
Yu, J. (2013). Netrin-1 rescues neuron loss by attenuating second-
ary apoptosis in ipsilateral thalamic nucleus following focal cere-
bral infarction in hypertensive rats. Neuroscience 231, 225–232.Stem Cell RepLo Sardo, V., Zuccato, C., Gaudenzi, G., Vitali, B., Ramos, C., Tar-
tari, M., Myre, M.A., Walker, J.A., Pistocchi, A., Conti, L., et al.
(2012). An evolutionary recent neuroepithelial cell adhesion func-
tion of huntingtin implicates ADAM10-Ncadherin. Nat. Neurosci.
15, 713–721.
Lobo, M.K., Karsten, S.L., Gray, M., Geschwind, D.H., and Yang,
X.W. (2006). FACS-array profiling of striatal projection neuron
subtypes in juvenile and adult mouse brains. Nat. Neurosci. 9,
443–452.
Margueron, R., and Reinberg, D. (2011). The Polycomb complex
PRC2 and its mark in life. Nature 469, 343–349.
Miller, J.P., Yates, B.E., Al-Ramahi, I., Berman, A.E., Sanhueza, M.,
Kim, E., de Haro, M., DeGiacomo, F., Torcassi, C., Holcomb, J.,
et al. (2012). A genome-scale RNA-interference screen identifies
RRAS signaling as a pathologic feature of Huntington’s disease.
PLoS Genet. 8, e1003042.
Molero, A.E., Gokhan, S., Gonzalez, S., Feig, J.L., Alexandre, L.C.,
and Mehler, M.F. (2009). Impairment of developmental stem
cell-mediated striatal neurogenesis and pluripotency genes in a
knock-in model of Huntington’s disease. Proc. Natl. Acad. Sci.
USA 106, 21900–21905.
Molina-Calavita, M., Barnat, M., Elias, S., Aparicio, E., Piel, M., and
Humbert, S. (2014). Mutant huntingtin affects cortical progenitor
cell division and development of themouse neocortex. J. Neurosci.
34, 10034–10040.
Onorati, M., Castiglioni, V., Biasci, D., Cesana, E., Menon, R.,
Vuono, R., Talpo, F., Goya, R.L., Lyons, P.A., Bulfamante, G.P.,
et al. (2014).Molecular and functional definition of the developing
human striatum. Nat. Neurosci. 17, 1804–1815.
Reis, S.A., Thompson, M.N., Lee, J.M., Fossale, E., Kim, H.H., Liao,
J.K., Moskowitz, M.A., Shaw, S.Y., Dong, L., Haggarty, S.J., et al.
(2011). Striatal neurons expressing full-length mutant huntingtin
exhibit decreased N-cadherin and altered neuritogenesis. Hum.
Mol. Genet. 20, 2344–2355.
Sakuma,M., Tanaka, E., Taru, H., Tomita, S., Gandy, S., Nairn, A.C.,
Nakaya, T., Yamamoto, T., and Suzuki, T. (2009). Phosphorylation
of the amino-terminal region of X11L regulates its interactionwith
APP. J. Neurochem. 109, 465–475.
Selman, C., Lingard, S., Choudhury, A.I., Batterham, R.L., Claret,
M., Clements, M., Ramadani, F., Okkenhaug, K., Schuster, E.,
Blanc, E., et al. (2008). Evidence for lifespan extension and delayed
age-related biomarkers in insulin receptor substrate 1 null mice.
FASEB J. 22, 807–818.
Seong, I.S., Woda, J.M., Song, J.-J., Lloret, A., Abeyrathne, P.D.,
Woo, C.J., Gregory, G., Lee, J.-M., Wheeler, V.C., Walz, T., et al.
(2010). Huntingtin facilitates polycomb repressive complex 2.
Hum. Mol. Genet. 19, 573–583.
Serra, H.G., Duvick, L., Zu, T., Carlson, K., Stevens, S., Jorgensen,
N., Lysholm, A., Burright, E., Zoghbi, H.Y., Clark, H.B., et al.
(2006). RORalpha-mediated Purkinje cell development determines
disease severity in adult SCA1 mice. Cell 127, 697–708.
Shi, L., Yue, J., You, Y., Yin, B., Gong, Y., Xu, C., Qiang, B., Yuan, J.,
Liu, Y., and Peng, X. (2006). Dok5 is substrate of TrkB and TrkC re-
ceptors and involved in neurotrophin induced MAPK activation.
Cell. Signal. 18, 1995–2003.orts j Vol. 5 j 1023–1038 j December 8, 2015 j ª2015 The Authors 1037
Southwell, A.L., Franciosi, S., Villanueva, E.B., Xie, Y., Winter, L.A.,
Veeraraghavan, J., Jonason, A., Felczak, B., Zhang, W., Kovalik, V.,
et al. (2015). Anti-semaphorin 4D immunotherapy ameliorates
neuropathology and some cognitive impairment in the YAC128
mouse model of Huntington disease. Neurobiol. Dis. 76, 46–56.
Strand, A.D., Baquet, Z.C., Aragaki, A.K., Holmans, P., Yang, L., Cle-
ren, C., Beal,M.F., Jones, L., Kooperberg, C., Olson, J.M., and Jones,
K.R. (2007). Expression profiling of Huntington’s disease models
suggests that brain-derived neurotrophic factor depletion plays a
major role in striatal degeneration. J. Neurosci. 27, 11758–11768.
The Huntington’s Disease Collaborative Research Group. (1993). A
novel gene containing a trinucleotide repeat that is expanded and
unstable onHuntington’s disease chromosomes. Cell 72, 971–983.
Tourette, C., Farina, F., Vazquez-Manrique, R.P., Orfila, A.M., Voi-
sin, J., Hernandez, S., Offner, N., Parker, J.A., Menet, S., Kim, J.,
et al. (2014). The Wnt receptor Ryk reduces neuronal and cell sur-
vival capacity by repressing FOXO activity during the early phases
of mutant huntingtin pathogenicity. PLoS Biol. 12, e1001895.1038 Stem Cell Reports j Vol. 5 j 1023–1038 j December 8, 2015 j ª2015 ThVawter, M.P., Dillon-Carter, O., Tourtellotte, W.W., Carvey, P., and
Freed, W.J. (1996). TGFbeta1 and TGFbeta2 concentrations are
elevated in Parkinson’s disease in ventricular cerebrospinal fluid.
Exp. Neurol. 142, 313–322.
Victorson, D., Carlozzi, N.E., Frank, S., Beaumont, J.L., Cheng, W.,
Gorin, B., Duh, M.S., Samuelson, D., Tulsky, D., Gutierrez, S., et al.
(2014). Identifying motor, emotional-behavioral, and cognitive
deficits that comprise the triad ofHD symptoms frompatient, care-
giver, and provider perspectives. Tremor Other Hyperkinet. Mov.
(N. Y.) 4, 224.
Videnovic, A. (2013). Treatment of huntington disease. Curr. Treat.
Options Neurol. 15, 424–438.
Zetterberg, H., Andreasen, N., and Blennow, K. (2004). Increased
cerebrospinal fluid levels of transforming growth factor-beta1 in
Alzheimer’s disease. Neurosci. Lett. 367, 194–196.
Zhang, N., An, M.C., Montoro, D., and Ellerby, L.M. (2010). Char-
acterization of human Huntington’s disease cell model from
induced pluripotent stem cells. PLoS Curr. 2, RRN1193.e Authors
